GI Cancer Highlights From ASCO26: RASolute-302, BREAKWATER, and More

Dr. Megan Kruse and Dr. Hope Rugo discuss practice-changing data in metastatic breast cancer and critical shifts in the treatment of early-stage disease that were presented at the 2026 ASCO Annual Meeting. LINK TO FULL TRANSCRIPT

Dr. Neeraj Agarwal and Dr. Jeanny Aragon-Ching discuss high-impact abstracts in the treatment of prostate, bladder, and kidney cancers that were presented at the 2026 ASCO Annual Meeting. LINK TO FULL TRANSCRIPT

Dr. Pauline Funchain and Dr. Allison Betof discuss practice-changing and paradigm-shifting abstracts in melanoma, Merkel cell carcinoma, and cellular therapies that were presented at the 2026 ASCO Annual Meeting. LINK TO FULL TRANSCRIPT

Dr. Nilo Azad and Dr. Aparna Parikh discuss high-impact studies in gastrointestinal cancers and other novel treatment approaches that were presented at the 2026 ASCO Annual Meeting. LINK TO FULL TRANSCRIPT

Dr. Marc Braunstein and Dr. Adam Kittai highlight top research on hematologic malignancies from the 2026 ASCO Annual Meeting, including studies on lymphoid malignancies, multiple myeloma, and plasma cell disorders. LINK TO FULL TRANSCRIPT  

Dr. Christine Lovly and Dr. Vamsi Velcheti discuss practice-changing lung cancer data presented at the 2026 ASCO Annual Meeting, including key studies on squamous cell lung cancer, NSCLC, and SCLC. LINK TO FULL TRANSCRIPT

Dr. Monty Pal shares highlights from the final day of ASCO26, including new research on treating anemia in myelofibrosis, advances in RAS-mutated mCRC, novel therapies for AML, and a potentially practice-changing trial in TNBC. LINK TO FULL TRANSCRIPT

Dr. Monty Pal shares highlights from Day 4 of the 2026 ASCO Annual Meeting, including a much-anticipated study in hepatocellular carcinoma, new data in non–small cell lung cancer, and a key update in the treatment of Merkel cell carcinoma. LINK TO TRANSCRIPT

Dr. Monty Pal shares highlights from Day 3 of the 2026 ASCO Annual Meeting, including new research for the treatment of advanced CRC and mCRPC, TIL cell therapy in advanced non-uveal melanoma, and an ultra-low dose immunotherapy trial in head and neck squamous cell carcinoma. LINK TO FULL TRANSCRIPT

Dr. Monty Pal shares highlights from Day 2 of the 2026 ASCO Annual Meeting, including a practice-changing trial in renal cell carcinoma, advances in ER-positive, HER2-negative early breast cancer, and the use of olanzapine as an effective steroid-sparing alternative for chemo-induced nausea and vomiting in pediatric cancer. LINK TO FULL TRANSCRIPT